01
Med-Fine FamilyFinancing Progress
1. Dual-Targeting ADC Drug Development PlatformPhrontline BiopharmaCompleted over 100 million yuan in Pre-A round financing, committed to becoming the international leader in "next-generation ADC"
Recently, Phrontline Biopharma, a leading dual-antibody ADC company in China, announced the completion of a Pre-A round of financing exceeding 100 million yuan, exclusively invested by Decheng Capital, with Index Capital serving as the exclusive financial advisor. After this round of financing, Phrontline Biopharma will increase its R&D investment, accelerate the advancement of multiple preclinical pipelines, upgrade its proprietary technology platform, and move faster towards the vision of "becoming a global leading pharmaceutical company."Learn More
2. AccuPulseAccuPulse Medical Technology Co., Ltd. Secures Additional Investment from Blue Bay Sci-Tech Group to Strengthen the Commercialization of China-Made Pulse Ablation and 3D Mapping SystemsFollowing the nearly 200 million yuan Series A+ financing round in February, led by the Shanghai Biomedical Industry Fund and the Shaoxing Binhai New Area Biomedical Industry Equity Investment Fund managed by Shengshi Investment, AccuPulse Medical Technology Co., Ltd. (referred to as "AccuPulse") has received an additional 50 million yuan investment from Lanwan Capital Group. This round of financing will still be used to advance the research and development and commercial operations of the company's core products, the pulsed field ablation and 3D mapping systems.Learn More
02
Med-Fine FamilyR&D Progress
1. AccuPulsePublication of Phase I Clinical Data for EX103, a CD20×CD3 Bispecific Antibody, in Treating Patients with Severe Relapsed/Refractory B-NHLThe 2024 Annual Meeting of the American Society of Clinical Oncology (2024 ASCO Annual Meeting) was held in Chicago, USA, from May 31 to June 4 local time. This meeting is one of the most important annual events in the global oncology field, bringing together top experts to share the latest research findings and treatment technologies in oncology. EX103, an innovative CD20×CD3 bispecific antibody developed by Phrontline Biopharma, was presented in a poster session showcasing the latest Phase I clinical trial data.Learn More
2. DanQing PharmaceuticalsChina's First PARG Inhibitor IND Approved in the U.S.June 24, 2024, Beijing, China, Boston, USA — DanQing Pharmaceuticals announced that the Investigational New Drug (IND) application for DAT-2645, China’s first PARG inhibitor, was approved by the U.S. Food and Drug Administration (FDA) on June 22. This is the first PARG inhibitor from China and among the first two globally to receive FDA approval for clinical trials.Learn More
3. World's First! Shanghai Children's Medical Center CollaboratesKejin BioFirst PKD Child Successfully Treated with Gene Replacement Therapy, Initial Clinical Study Shows Promising ResultsRecently, the transplantation team of the Hematology and Oncology Department at the National Children's Medical Center (Shanghai), Shanghai Children's Medical Center affiliated with Shanghai Jiao Tong University School of Medicine, successfully performed precise large-fragment gene replacement therapy on a 16-year-old patient with pyruvate kinase deficiency (PKD). This marks the world's first case of PKD treatment using gene replacement therapy, potentially ushering in a new era for PKD treatment.Learn More
4. Libang PharmaceuticalsInnovative Drug AP306 Under Development Receives Breakthrough Therapy Designation from the National Medical Products Administration for the Treatment of Hyperphosphatemia in Chronic Kidney DiseaseShanghai, China, June 25, 2024 — Alebund Pharmaceuticals, a comprehensive biopharmaceutical company focused on developing innovative drugs for the treatment of kidney diseases and other related chronic conditions, announced that its investigational new drug AP306 has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of hyperphosphatemia in chronic kidney disease.Learn More
5. AccuPulse MedicalPublic Disclosure of Review Reports for New Class III IVD ProductsOn May 30, 2024, the Center for Medical Device Evaluation of the National Medical Products Administration publicly released the technical evaluation report for the registration of the product "Mitochondrial Gene 3243A>G Mutation Detection Kit (Fluorescence PCR Method)." Applicant: Jiajian (Guangzhou) Bioengineering Technology Co., Ltd.Learn More
6. The Lancet Sub-Journal ReleaseTian GuangshiClinical 1b/2 Phase Research Results of the New Generation CD20 Antibody MIL62Recently, eClinical Medicine, a subsidiary journal of the authoritative international journal The Lancet, published the Phase 1b/2 clinical research results of MIL62 recombinant humanized monoclonal antibody injection, led by Professor Shi Yuankai from the Cancer Hospital of the Chinese Academy of Medical Sciences, in combination with lenalidomide for the treatment of relapsed/refractory follicular lymphoma and marginal zone lymphoma. This study aims to evaluate the efficacy and safety of MIL62 combined with lenalidomide in treating relapsed/refractory follicular lymphoma and marginal zone lymphoma.Learn More
7. SinoMicroAccuPulse's Self-Developed Fully Electric Stapler Approved as Beijing Innovative Medical DeviceRecently, the Beijing Municipal Medical Products Administration announced the fifth batch of innovative medical device products in Beijing for 2024. SonoMicro's independently developed disposable electric endoscopic cutting stapler and cartridge have been approved as innovative medical devices in Beijing due to their innovativeness.Learn More
03
Med-Fine FamilyBusiness Breakthrough
1. WuxiSaifuPhrontline Biopharma Technology Co., Ltd. Successfully Opens for BusinessOn the morning of June 24, 2024, the opening ceremony of Wuxi Saifu Guotong Pharmaceutical Technology Co., Ltd. was successfully held. Wuxi Saifu Guotong Pharmaceutical Technology Co., Ltd., hereinafter referred to as Saifu Guotong (Wuxi), owns China's first private enterprise-level radioactive GLP laboratory, Wuxi's first experimental base for non-clinical evaluation of nuclear medicine, and also has the qualification to use all medical radionuclides. It can provide integrated production and R&D technical services for radiopharmaceuticals (CR/DMO) that comply with the regulatory requirements of regional/regulatory agencies such as FDA, NMPA, and OECD, including services from CDMO to pharmacology/toxicology, drug metabolism, isotope molecular imaging, and mass balance studies.Learn More
2. XinCheng MedicalMoyoAssist® Extra-VAD Completes China's First Commercial ApplicationOn June 19, 2024, the team led by Professor Dong Nianguo from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, completed the first nationwide commercial application of MoyoAssist® Extra-VAD (fully magnetically levitated external artificial heart) in China. The device successfully bridged a patient with acute heart failure following a myocardial infarction to a long-term implantable artificial heart after six days of support.Learn More
3. HeartScape TechnologiesMultiple products implemented in renowned hospitals
In June 2024, the VR product series by Xinjing Technology were installed in multiple locations. Among them, the VR Mental Health Training System was installed at Xiangya Second Hospital of Central South University; the VR Cognitive Ability Assessment and Training Software (Substance Dependence Edition) and "Xinjing Anmeng" Sleep Disorder Auxiliary Treatment Software were installed at Lishui Second People's Hospital; the VR Cognitive Ability Assessment and Training Software (Substance Dependence Edition) was installed at Shandong Mental Health Center; and the VR Attention Assessment and Training System was installed at Huize County Maternal and Child Health Care Hospital in Yunnan Province.Learn More
4. CAS GenomicsFull Marks Achieved in High-Throughput Sequencing Detection of Tumor Cell-Free DNA Gene Mutations
Recently, the National Center for Clinical Laboratories (NCCL) under the National Health Commission of China released the 2024 report on the External Quality Assessment (EQA) of high-throughput sequencing detection of tumor cell-free DNA gene mutations across China. Nantong AccuGene Medical Laboratory, under AccuGene, successfully passed this EQA activity with a perfect score of 100 points, once again demonstrating its technical strength in the high-throughput sequencing detection of tumor cell-free DNA gene mutations.Learn MoreMed-Fine FamilyBusiness Cooperation
1. Saifu PharmaceuticalsStrongly Collaborating with Phrontline Biopharma to Build an End-to-End CR/DMO One-Stop Radiopharmaceutical Service PlatformSaifu Pharmaceuticals and Guotong New Drug jointly establish a radiomolecular imaging and radiopharmaceutical evaluation service platform. Through joint investment and construction, they further strengthen their cooperative relationship, achieving complementary advantages, innovative development, resource sharing, and win-win cooperation.Learn More
2. CDMO Empowers Enterprises to Explore "New Horizons",Shuimu JihengAssisting Cayud Biotech in Obtaining Certification for Its COVID-19 Antigen Test Kit
Recently, Beijing Shuimu Jiheng Biotechnology Co., Ltd. assisted Beijing Caryl Biotech Co., Ltd. in obtaining the Class III Medical Device Registration Certificate (Registration No. 20243401101) from the National Medical Products Administration (NMPA) for their independently developed COVID-19 (2019-nCoV) Antigen Test Kit (Latex Method), offering new solutions for early rapid testing, home self-testing, and primary healthcare.Learn More3. World's First Certification!Shuimu MedicalAssisting Kunmai Medical's Liquid-Helium-Free Quantum Magnetoencephalography in Obtaining Approval
Recently, Zhongguan Village Shuimu Medical assisted Kunmai Medical in the independent development of the innovative medical device "Magnetoencephalography System," which has received NMPA approval for marketing (Registration Certificate No.: Jingxiangzhun 20242070274). This product has become the world's first helium-free magnetoencephalography system based on Atomic Magnetometer (also known as Optically Pumped Magnetometer, or OPM) technology to be clinically approved.Learn More
4.YipinHelping Leading Orthopedic Companies Obtain Three Class III Registration Certificates in a Row
Recently, three orthopedic implant devices from a Beijing-based orthopedic company have been approved for registration and market launch by the National Medical Products Administration (NMPA)! The three products are: Femoral Head Reconstruction Rod, Tantalum Metal Filler Block, and Porous Tantalum Metal Interbody Fusion Device. Yipin Laboratory comprehensively verified the safety and efficacy of these three products through the establishment of a beagle bone defect model, based on results including blood indicators of experimental animals, imaging examinations (CT and Micro-CT), histopathological changes, wound and bone defect healing conditions, and bone ingrowth within the pores of porous materials.Learn More
5. ZD Medical®Strategic Cooperation Reached with AccuPulse Medical Technology Co., Ltd.On the morning of June 12, ZD Medical® and Jianjia Medical Investment Management Co., Ltd. signed a strategic cooperation agreement at the headquarters of Jianjia Medical. Wang Daoyu, Chairman and CEO of ZD Medical®, Chief Operating Officer Zhao Qingxiao, Wei Yulin, Executive Director and CEO of Jianjia Medical, General Manager Feng Jie, General Manager Assistant and Minister of Supply Chain Management Wang He, as well as representatives from relevant functional departments attended the meeting. The meeting was presided over by Wang He, General Manager of Jianjia Medical. Wang Daoyu, Chairman and CEO of ZD Medical®, and Feng Jie, General Manager of Jianjia Medical, signed the agreement on behalf of both parties.Learn More05
Med-Fine FamilyIndustry Honors
1. Orange Sails PharmaceuticalsSuccessfully Advanced to the Semi-finals of the 4th "Haiju Yingcai" Global Innovation and Entrepreneurship Competition2. Saifu PharmaceuticalsAwarded "TOP10" in the Annual Outstanding Supplier of Domestic CXO Services in the Biomedical Innovation Field of the "Starlight List"3. ChinaDepartmentSaifuScientific and Technological Achievements Honored with the First Prize of the "2024 Science and Technology Award" by Hebei Pharmaceutical Association4. Tian GuangshiSuccessfully selected for the "Top 30 Most Innovative Antibody Drug Companies in China" for four consecutive years5. HanYu MedicalListed in the "China Unicorn Enterprise Research Report 2024" - Innovative Medical Device Company6. Water, Wood, Metal AscensionYu Qiong Selected for the First Batch of Expert Database of Beijing Medical and Health Science and Technology Promotion Center in 20247. GuiyangEpiPointSuzhouEpiPointBoth AccuPulse and Phrontline Biopharma Receive "Specialized, Precise, Unique, and Innovative" Honorary Titles8. ZD Medical®Awarded the First Prize of Shanghai Rehabilitation Medicine Science and Technology Award 20249. West Lake OmicsHonored as the World Economic Forum 2024 "Global Technology Pioneer"10. Yibo HospitalAwarded the Most Popular Award and Second Prize in the East China Regional Assistive Device Case Report Competition11. AccuPulse Health Fund Ranks on 2024 ""Beyond the Trough" - LP CLUB Private Equity Investment Industry Increased Attention List
